Dry Eye

In this podcast episode, Ophthalmology Times' co-chief medical editors Peter J. McDonnell, MD, and Neda Shamie, MD, delve into the clinical nuances of Demodex blepharitis. Through personal anecdotes, they stress its underrecognized gravity and discuss diagnostic cues like collarettes. The experts share their enthusiasm for improved treatments, echoing the transformative impact seen in dry eye care.

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

For clinicians, the evolution of treatment is as much a responsibility as an opportunity.

Treating the meibomian glands and lifestyle changes are among some of the treatment methods.

Lead author Sean Paul, MD, reports radiofrequency treatment in conjunction with expression of the meibomian glands reduces the signs and symptoms of dry eye disease.

Selina McGee, OD, FAAO, emphasizes the significance of a multifactorial treatment approach for dry eye, especially in patients concurrently using other eye drops or contact lenses, and advocates for ocular sparing therapies when needed.

Selina McGee, OD, FAAO, reviews a challenging case involving a patient with advanced glaucoma on multiple medications, grappling with multifactorial dry eye.

Selina McGee, OD, FAAO, shares her comprehensive examination and treatment approach, underscoring the importance of tailoring treatments based on the individual's dry eye evaluation.

Selina McGee, OD, FAAO, presents a patient case referred for ocular surface optimization in preparation for cataract surgery.

John Sheppard, MD, explains the potential harm caused by over-the-counter artificial tears with preservatives on the ocular surface and discusses innovative ocular-sparing treatments that stimulate tear production.

John Sheppard, MD, reviews the case of a 63-year-old male with evaporative dry eye, facing challenges in managing his symptoms using over-the-counter artificial tears.

John Sheppard, MD, discusses the impact of continuous contact lens use on dry eye, often masking its signs, and explores treatment strategies for patients using contact lenses.

John Sheppard, MD, presents a dry eye case involving a 48-year-old female patient who has been using contact lenses for approximately three decades.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Experts conclude their discussion sharing clinical peals on the management of dry eye disease (DED) and how providers may invest in their practice to better screen and treat their patients.

Experts discuss their clinical approaches for co-managing patients with dry eye disease and how they educate patients and their providers about the disease.

Crystal Brimer, OD, and Kelly K. Nichols, OD, MPH, PhD, discuss two treatments, AZR-MD-001 and Reproxalap, that are in the pipeline to treat patients with dry eye disease (DED).

Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss three new FDA-approved therapies for the treatment of dry eye disease (DED).

Physicians ask the right questions and take an aggressive approach to treatment.

Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.